The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
 
Joao Victor Machado Alessi
No Relationships to Disclose
 
Carolyn Glass
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Liam F. Spurr
Employment - Genzyme (I)
Stock and Other Ownership Interests - CRISPR Therapeutics; Vertex
 
Lynette M. Sholl
Honoraria - AstraZeneca
Consulting or Advisory Role - Foghorn Therapeutics; Loxo
Research Funding - Roche/Genentech
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)